Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by raven16on Aug 03, 2021 10:32pm

280 Views

Post# 33646753

Folks AntibeTrash Is A Shorter And Doesn't Care

About Antibe And Only Wants To Drive The Price Down,These Clowns Are Everywhere On The Stockboard, If You Look He Just Signed Onto Stockhouse Yesterday And Me Thinks He Is An Insider Who May Have Been Privy To Information That None Of Us Got Until Today,Worth Looking Into I Think.

<< Previous

Bullboard Posts

Next >>

Bombardier delivers Global 6500 aircraft to U.S. Army